Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (mCRC).Celine Hoyek, Tanios Bekaii‐Saab, Mitesh J. Borad et al.|Journal of Clinical Oncology|2025Cited by 4
Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC).Celine Hoyek, Tanios Bekaii‐Saab, Angelo Pirozzi et al.|Journal of Clinical Oncology|2025Cited by 0
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in <i>TP53</i> -mutated advanced biliary tract cancer.Taro Shibuki, Masafumi Ikeda, Celine Hoyek et al.|Journal of Clinical Oncology|2025Cited by 0
Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract CancerTanios Bekaii‐Saab, Masafumi Ikeda, Binbin Zheng-Lin et al.|Research Square|2025Cited by 0
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysisBinbin Zheng-Lin, Tanios Bekaii-Saab, Taro Shibuki et al.|npj Precision Oncology|2026Cited by 0